These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 17059563)

  • 21. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model.
    Pérez M; Hernández F; Lim F; Díaz-Nido J; Avila J
    J Alzheimers Dis; 2003 Aug; 5(4):301-8. PubMed ID: 14624025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration.
    Li HL; Wang HH; Liu SJ; Deng YQ; Zhang YJ; Tian Q; Wang XC; Chen XQ; Yang Y; Zhang JY; Wang Q; Xu H; Liao FF; Wang JZ
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3591-6. PubMed ID: 17360687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.
    Hernández F; Borrell J; Guaza C; Avila J; Lucas JJ
    J Neurochem; 2002 Dec; 83(6):1529-33. PubMed ID: 12472906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of glycogen synthase kinase-3 reverses tau hyperphosphorylation induced by Pin1 down-regulation.
    Xiong YS; Wang DL; Tan L; Wang X; Chen LM; Gong CX; Wang JZ; Zhu LQ
    CNS Neurol Disord Drug Targets; 2013 May; 12(3):436-43. PubMed ID: 23469846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.
    Lucas JJ; Hernández F; Gómez-Ramos P; Morán MA; Hen R; Avila J
    EMBO J; 2001 Jan; 20(1-2):27-39. PubMed ID: 11226152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
    Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation.
    Sahara N; Murayama M; Lee B; Park JM; Lagalwar S; Binder LI; Takashima A
    Eur J Neurosci; 2008 Jun; 27(11):2897-906. PubMed ID: 18540881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3β activity in SH-SY5Y cells.
    Wu X; Kosaraju J; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():101-108. PubMed ID: 28359686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
    Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β.
    Jiang J; Wang ZH; Qu M; Gao D; Liu XP; Zhu LQ; Wang JZ
    Sci Rep; 2015 Jun; 5():11765. PubMed ID: 26119563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurofibrillary tangles and tau phosphorylation.
    Brion JP; Anderton BH; Authelet M; Dayanandan R; Leroy K; Lovestone S; Octave JN; Pradier L; Touchet N; Tremp G
    Biochem Soc Symp; 2001; (67):81-8. PubMed ID: 11447842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line.
    Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI
    Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
    Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
    Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons.
    Takahashi M; Yasutake K; Tomizawa K
    J Neurochem; 1999 Nov; 73(5):2073-83. PubMed ID: 10537067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tau overexpression in transgenic mice induces glycogen synthase kinase 3beta and beta-catenin phosphorylation.
    Shim SB; Lim HJ; Chae KR; Kim CK; Hwang DY; Jee SW; Lee SH; Sin JS; Leem YH; Lee SH; Cho JS; Lee HH; Choi SY; Kim YK
    Neuroscience; 2007 May; 146(2):730-40. PubMed ID: 17337327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease.
    Sze CI; Su M; Pugazhenthi S; Jambal P; Hsu LJ; Heath J; Schultz L; Chang NS
    J Biol Chem; 2004 Jul; 279(29):30498-506. PubMed ID: 15126504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.